Jazz Pharmaceuticals’ (JAZZ) “Overweight” Rating Reaffirmed at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating reaffirmed by stock analysts at Piper Sandler in a research note issued on Wednesday,Benzinga reports. They presently have a $176.00 target price on the specialty pharmaceutical company’s stock, up from their previous target price of $163.00. Piper Sandler’s target price indicates a potential upside of 22.84% from the stock’s previous close.

Several other brokerages have also recently weighed in on JAZZ. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday. TD Cowen reduced their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Stock Down 0.6 %

NASDAQ JAZZ opened at $143.27 on Wednesday. The stock has a market capitalization of $8.66 billion, a P/E ratio of 20.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a fifty day moving average of $125.87 and a 200-day moving average of $118.62.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 over the last 90 days. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new position in Jazz Pharmaceuticals during the 4th quarter worth about $59,668,000. Dimensional Fund Advisors LP raised its stake in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after purchasing an additional 320,724 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp boosted its position in shares of Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after buying an additional 296,800 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.